Eluding anaphylaxis allows peptide-specific prevention of the relapsing stage of experimental autoimmune encephalomyelitis

Keith W. Wegmann, H. G. Archie Bouwer, Ruth Whitham, David J. Hinrichs

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We have used a peptide derived from Acanthamoeba castellanii (ACA) to treat the relapsing phase of EAE that develops in SJL mice following immunization with the PLP 139-151 peptide. The native sequence of the ACA 81-95 peptide that shares key residues with the PLP 139-151 peptide is weakly encephalitogenic in SJL mice but is not recognized by antiserum from SJL mice immunized with PLP 139-151. A single amino acid change to the ACA 81-95 peptide sequence significantly enhanced its encephalitogenicity. When administered to SJL mice as a nonlinear peptide octamer, the modified ACA peptide prevented relapsing episodes of EAE in SJL mice previously immunized with the PLP 139-151 encephalitogenic peptide.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalJournal of Neuroimmunology
Volume274
Issue number1-2
DOIs
StatePublished - 2014

Fingerprint

Autoimmune Experimental Encephalomyelitis
Anaphylaxis
Acanthamoeba castellanii
Peptides
Immune Sera
Immunization
Amino Acids
myelin proteolipid protein (139-151)

Keywords

  • Peptide mimic
  • Peptide octamer
  • Prevention of relapsing disease
  • Relapsing EAE

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Eluding anaphylaxis allows peptide-specific prevention of the relapsing stage of experimental autoimmune encephalomyelitis. / Wegmann, Keith W.; Archie Bouwer, H. G.; Whitham, Ruth; Hinrichs, David J.

In: Journal of Neuroimmunology, Vol. 274, No. 1-2, 2014, p. 46-52.

Research output: Contribution to journalArticle

@article{2c32df70dd2f42429b8254e15e416d40,
title = "Eluding anaphylaxis allows peptide-specific prevention of the relapsing stage of experimental autoimmune encephalomyelitis",
abstract = "We have used a peptide derived from Acanthamoeba castellanii (ACA) to treat the relapsing phase of EAE that develops in SJL mice following immunization with the PLP 139-151 peptide. The native sequence of the ACA 81-95 peptide that shares key residues with the PLP 139-151 peptide is weakly encephalitogenic in SJL mice but is not recognized by antiserum from SJL mice immunized with PLP 139-151. A single amino acid change to the ACA 81-95 peptide sequence significantly enhanced its encephalitogenicity. When administered to SJL mice as a nonlinear peptide octamer, the modified ACA peptide prevented relapsing episodes of EAE in SJL mice previously immunized with the PLP 139-151 encephalitogenic peptide.",
keywords = "Peptide mimic, Peptide octamer, Prevention of relapsing disease, Relapsing EAE",
author = "Wegmann, {Keith W.} and {Archie Bouwer}, {H. G.} and Ruth Whitham and Hinrichs, {David J.}",
year = "2014",
doi = "10.1016/j.jneuroim.2014.06.011",
language = "English (US)",
volume = "274",
pages = "46--52",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Eluding anaphylaxis allows peptide-specific prevention of the relapsing stage of experimental autoimmune encephalomyelitis

AU - Wegmann, Keith W.

AU - Archie Bouwer, H. G.

AU - Whitham, Ruth

AU - Hinrichs, David J.

PY - 2014

Y1 - 2014

N2 - We have used a peptide derived from Acanthamoeba castellanii (ACA) to treat the relapsing phase of EAE that develops in SJL mice following immunization with the PLP 139-151 peptide. The native sequence of the ACA 81-95 peptide that shares key residues with the PLP 139-151 peptide is weakly encephalitogenic in SJL mice but is not recognized by antiserum from SJL mice immunized with PLP 139-151. A single amino acid change to the ACA 81-95 peptide sequence significantly enhanced its encephalitogenicity. When administered to SJL mice as a nonlinear peptide octamer, the modified ACA peptide prevented relapsing episodes of EAE in SJL mice previously immunized with the PLP 139-151 encephalitogenic peptide.

AB - We have used a peptide derived from Acanthamoeba castellanii (ACA) to treat the relapsing phase of EAE that develops in SJL mice following immunization with the PLP 139-151 peptide. The native sequence of the ACA 81-95 peptide that shares key residues with the PLP 139-151 peptide is weakly encephalitogenic in SJL mice but is not recognized by antiserum from SJL mice immunized with PLP 139-151. A single amino acid change to the ACA 81-95 peptide sequence significantly enhanced its encephalitogenicity. When administered to SJL mice as a nonlinear peptide octamer, the modified ACA peptide prevented relapsing episodes of EAE in SJL mice previously immunized with the PLP 139-151 encephalitogenic peptide.

KW - Peptide mimic

KW - Peptide octamer

KW - Prevention of relapsing disease

KW - Relapsing EAE

UR - http://www.scopus.com/inward/record.url?scp=84906935161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906935161&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2014.06.011

DO - 10.1016/j.jneuroim.2014.06.011

M3 - Article

C2 - 24997489

AN - SCOPUS:84906935161

VL - 274

SP - 46

EP - 52

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -